Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F24%3A00080425" target="_blank" >RIV/65269705:_____/24:00080425 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/24:00137305 RIV/00098892:_____/24:10158748 RIV/00843989:_____/24:E0111109 RIV/00064190:_____/24:10001319
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S095461112400266X?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S095461112400266X?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.rmed.2024.107791" target="_blank" >10.1016/j.rmed.2024.107791</a>
Alternative languages
Result language
angličtina
Original language name
Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study
Original language description
Background: There is a lack of data on the long-term effect of nintedanib on survival in specific groups of idiopathic pulmonary fibrosis (IPF) patients with different phenotypes. We investigated the outcomes of nintedanib therapy in an observational study of a large multicentre real-world cohort of IPF patients with various initial characteristics. Methods: The analysis included IPF patients treated with nintedanib (NIN) and IPF patients not receiving anti- fibrotic treatment (NAF) enrolled for the EMPIRE registry in 2015-2020. The patients were stratified according to their initial FVC predicted, dyspnoea, UIP pattern and age. All-cause mortality and annual rate of FVC decline were the main endpoints. Cox proportional hazards model for survival assessment and linear mixed-effects model for FVC decline modelling were used. Results: A total of 869 NIN patients and 691 NAF patients were eligible for the analysis. The annual FVC decline rate was significantly different (adjusted values-0.053 l/yr vs-0.122 l/yr; p = 0.001). The adjusted hazard ratio (HR) for mortality was 0.40 (95 % CI 0.3 to 0.53, p < 0.001). The most significant effect of nintedanib was demonstrated in patients with impaired lung function, i.e., with an FVC predicted to be less than 80 % and a NYHA II to IV. Nintedanib therapy also reduced the difference in survival between men and women. Conclusions: Modelling confirmed that NIN therapy reduced differences in OS between patients with better and worse initial conditions and prognosis. Our results indicate that NIN is particularly beneficial for patients with advanced IPF and more severe phenotypes. Trial registration: EMPIRE was registered as a non-interventional post-registration study at the State Institute for Drug Control of the Czech Republic under ID 1412080000 on December 8, 2014.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30203 - Respiratory systems
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Respiratory Medicine
ISSN
0954-6111
e-ISSN
1532-3064
Volume of the periodical
234
Issue of the periodical within the volume
2024
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
107791
UT code for WoS article
001318539800001
EID of the result in the Scopus database
2-s2.0-85203511425